Core Viewpoint - The company, Sunlight Nuohe (688621.SH), is making a strategic investment of 20 million yuan in Shanghai Biling Biotechnology Co., Ltd. to enhance its position in the innovative drug industry, particularly in the field of novel nano-conjugated drugs and precise nano-delivery systems [1] Investment Details - The company will invest 20 million yuan to subscribe for an additional registered capital of 82,661 yuan in Biling Biotechnology, resulting in a 2.0435% equity stake in the company [1] - This investment is part of the company's broader strategy to strengthen its innovative drug industry chain [1] Technology and Market Potential - Biling Biotechnology specializes in novel nano-conjugated drugs and precise nano-delivery systems, which have significant application prospects in treating major diseases such as cancer [1] - The core technology platform of Biling can effectively enhance drug targeting and delivery efficiency, indicating a strong market potential [1] Strategic Alignment - The investment allows the company to enter the cutting-edge nano-drug technology sector, creating synergies with its existing business [1] - This move is expected to enrich the company's technological reserves and pipeline layout in innovative drug research and development, thereby enhancing its overall competitiveness in the pharmaceutical industry [1]

Core Viewpoint - Sunshine Nuohua (688621.SH) is advancing its strategic layout in the field of novel nano-conjugated drugs and precise nano-delivery by investing 20 million yuan to increase its stake in Biling Biotechnology [1] Group 1: Investment and Stake Acquisition - The company plans to use its own funds to invest 20 million yuan to subscribe to an increase in registered capital of 8.2661 thousand yuan in Biling Biotechnology, resulting in a 2.0435% equity stake [1] Group 2: Company Overview - Biling Biotechnology, established in May 2021, focuses on the research and development of novel nano-conjugated drugs and precise nano-delivery technologies [1] - The company has formed a multidisciplinary R&D team covering biology, chemistry, materials, engineering, and nanotechnology [1] Group 3: Technological Advancements - Biling Biotechnology has developed three core technology platforms: nano-mediated conjugated drug technology platform, small molecule-small molecule self-assembly nano-technology platform, and continuous intelligent manufacturing platform for nano-drugs [1] - The company has successfully established a full-chain technology barrier for nano-drugs from R&D to production, utilizing proprietary high-throughput continuous manufacturing processes and equipment [1] Group 4: Innovation and Clinical Development - Biling Biotechnology aims to create breakthrough therapies that are "more effective, safer, more convenient, and more economical" through a four-dimensional integration of new materials, new technologies, new equipment, and new drugs [1] - The company has submitted over ten invention patents, with several granted in regions such as China, the US, Europe, and Japan; multiple drug candidates are accelerating towards clinical trials [1]

Core Viewpoint - The company plans to invest 20 million yuan in BiLing Bio to acquire a 2.0435% stake, enhancing its strategic positioning in the nanomedicine sector [1] Group 1: Investment Details - The investment will be made using the company's own funds to subscribe to an increase in registered capital of 82,661 yuan in BiLing Bio [1] - The investment has been approved by the company's general manager office meeting and does not constitute a related party transaction or a major asset restructuring [1] Group 2: Target Company Overview - BiLing Bio focuses on the research and development of novel nano-conjugated drugs and precise nano-delivery technologies [1] - In the previous year, BiLing Bio reported a revenue of 481,100 yuan and a net loss of 40,859,500 yuan [1] Group 3: Strategic Implications - This investment allows the company to enter the nanomedicine market, which is seen as a strategic opportunity [1] - However, the target company may face operational and market risks [1]